Biocartis Group NV has signed an agreement with Nichirei Bioscience for the product registration and exclusive distribution of Biocartis' molecular diagnostic (MDx) oncology tests in Japan, operating on the fully automated sample-to-result Idylla(TM) platform. Under the terms of the agreement, Nichirei Bioscience will seek the regulatory approval of Idylla(TM) MDx oncology tests with the Japanese Ministry of Health, Labor and Welfare. Upon successful registration, Nichirei Bioscience's sale force plans to distribute Biocartis' Idylla(TM) platform across its commercial network of some 2,000 pathology laboratories in Japan.